期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型口服抗凝药达比加群酯研究进展 被引量：14

Research Progress in Novel Oral Anticoagulant: Dabigatran Etexilate
下载PDF
导出
摘要 达比加群酯是一种新型合成的直接凝血酶抑制剂,口服经胃肠吸收后,在体内转化为具有直接抗凝血活性的达比加群。现主要对达比加群酯的药理学、相关临床研究、临床应用前景进行综述。 Dabigatran etexilate is the prodrug of dabigatran,a potent,nonpeptidic small molecule that specifically and reversibly inhibits both free and clot-bound thrombin by binding to the active site of the thrombin molecule.This review provides an overview of the pharmacology of dabigatran etexilate,and describes the most recent published data on clinical trials with the new oral anticoagulants.
作者 肖宜超 刘启明
机构地区 中南大学湘雅二医院心血管内科
出处 《心血管病学进展》 CAS 2011年第4期575-578,共4页 Advances in Cardiovascular Diseases
关键词 抗凝药 达比加群酯 凝血酶抑制剂 心房颤动 静脉血栓栓塞 anticoagulant dabigatran etexilate direct thrombin inhibitor atrial fibrillation venous thromboembolism
分类号 R973.2 [医药卫生—药品]
  • 相关文献

参考文献31

  • 1Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vita- min K antagonists : American College of Chest Physicians Evidence-Based Clini- cal Practice Guidelines ( 8th Edition) [ J ]. Chest, 2008,133 ( 6 suppl) : 160S- 198S.
  • 2Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxa- ban[J]. Methods Mol Bial, 2010,663:181-201.
  • 3de Catefinan R, Kristensenb SD, Rendaa G. New anticoagulants for atrial fibril- lation[ J]. J Cardiovasc Med,2009,10:446-453.
  • 4Lee WM, Larrey D, Olsson R, et ah Hepatic findings in long-term clinical tri- Ms of ximelagatran[ J]. Drug Saf,2005,28(4) :351-370.
  • 5Stangier J, Rathgen K, Stahle H, et ah The pharmacokinetics, pharmacody- namics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects[J]. Br J Clin Pharmacol,2007,64(3) :292-303.
  • 6Haas S. New oral Xa and 1I a inhibitors: updates on clinical trial results[J]. J Thromb Throrubolysis ,2008,25 ( 1 ) : 52-60.
  • 7Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmaeodynam- ics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects [J]. Clin Pharmacokinet,2008,47(1) :47-59.
  • 8Blech S, Ebner T, Ludwig-Schweninger E, et al. The metabolism and disposi- tion of the oral direct thrombin inhibitor, dabigatran, in humans [J]. Drug Metab Dispos,2008,36(2) :386-399.
  • 9Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynam- ics of dabigatran etexilate, an or',d direct thrombin inhibitor [ J ]. Clin Appl Thromb Hemost,2009,15 ( suppl 1 ) :9S-16S.
  • 10Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmaeodynamics of oral dabigatran etexilate : an open- label, parallel-group, single-centre study [ J ]. Clin Pbarmaeokinet, 2010,49 (4) :259-268.

二级参考文献10

  • 1Hauel NH,Nar H,Priepke H,et al.Structure-based design of novel potent nonpeptide thrombin inhibitors[].Journal of Medicinal Chemistry.2002
  • 2Wienen W,Stassen JM,Priepke H,et al.Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabigatran etexilate,on thrombus formation and bleeding time in rats[].Thrombosis and Haemostasis.2007
  • 3Wienen W,Stassen JM,Priepke H,et al.In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug,dabigatran etexilate[].Thrombosis and Haemostasis.2007
  • 4Stangier J,Eriksson BI,Dahl OE,et al.Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement[].Journal of Clinical Pharmacology.2005
  • 5Troconiz IF,Tillmann C,Liesenfeld KH,et al.Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate(BIBR 1048) in patients undergoing primary elective total hip replacement surgery[].Journal of Clinical Pharmacology.2007
  • 6Blech S,Ebner T,Ludwig-Schwellinger E,et al.The metabolism and disposition of the oral direct thrombin inhibitor,dabigatran,in humans[].Drug Metabolism and Disposition.2008
  • 7Eriksson BI,Dahl OE,Ahnfelt L,et al.Dose escalating safety study of a new oral direct thrombin inhibitor,dabigatran etexilate,in patients undergoing total hip replacement:BISTRO Ⅰ[].Journal of Thrombosis and Haemostasis.2004
  • 8Wienen,W,Stassen,JM,Priepke,H.Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis[].Journal of Thrombosis and Haemostasis.2007
  • 9Eriksson,BI,Dahl,OE,Buller,HR.A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial[].Journal of Thrombosis and Haemostasis.2005
  • 10Eriksson B I,Dahl O E.Oral dabigatran etexilate vs.subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:the RE-MODEL randomized trial[].Journal of Thrombosis and Haemostasis.2007

共引文献25

同被引文献164

引证文献14

二级引证文献49

心血管病学进展
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部